Guru Sonpavde, MD
In the era of immunotherapy, particularly considering its impact on genitourinary malignancies, many experts are looking to PD-1/PD-L1 inhibitors for their patients with urothelial carcinoma. However, chemotherapy is still a big player in the advanced-disease setting, making the treatment landscape quite varied.
State of the Science Summit™ on Genitourinary Cancers.
The biggest unmet need in the bladder cancer space is the treatment of cisplatin-ineligible patients, says Sonpavde. Patients with urothelial carcinoma who are ineligible to receive cisplatin have suboptimal survival with chemotherapy. Given that cisplatin plus chemotherapy improves survival in the advanced disease setting, it makes sense to give neoadjuvant chemotherapy before radical cystectomy in high-risk locally advanced or muscle-invasive bladder cancer, Sonpavde explains.
... to read the full story